Aligos director granted options on 5,860 shares

Aligos Therapeutics director Peter Hirth received a stock option grant for 5,860 shares of common stock at an exercise price of $5.50 per share.

Accepted by SEC EDGAR 06/29/2026 - 04:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aligos Therapeutics director Peter Hirth received a stock option grant for 5,860 shares of common stock at an exercise price of $5.50 per share. The option vests in full on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, assuming continuous service, and expires in 2036.

Insider Trade Summary

Grant/Award: 5,860 shares

Grant/Award 1 txn

Insider Hirth Peter

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,860	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,860 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

Key Figures

Option grant size: 5,860 options Exercise price: $5.50 per share Expiration date: June 25, 2036 +1 more

4 metrics

Option grant size 5,860 options Stock option award to director Peter Hirth

Exercise price $5.50 per share Strike price for granted stock options

Expiration date June 25, 2036 Option term end date

Post-grant derivative holdings 5,860 options Total options held after transaction

Key Terms

Stock Option (Right to Buy), exercise price, grant, award, or other acquisition, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 5.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest and become exercisable financial

"The shares subject to the option will vest and become exercisable as to 100%..."

continuous service financial

"subject to continuous service to the Issuer through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aligos Therapeutics (ALGS) report for Peter Hirth?

Aligos Therapeutics reported that director Peter Hirth received a stock option grant for 5,860 shares of common stock at a $5.50 exercise price. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What are the terms of Peter Hirth’s new Aligos Therapeutics (ALGS) stock options?

The new stock options give Peter Hirth the right to buy 5,860 Aligos common shares at $5.50 per share. They vest 100% on the earlier of the first anniversary of the grant or immediately before the 2027 annual meeting, subject to continuous service.

When do Peter Hirth’s Aligos Therapeutics (ALGS) options expire?

Peter Hirth’s stock options are scheduled to expire on June 25, 2036. He must exercise them before that date, once vested, to acquire up to 5,860 Aligos common shares at the fixed $5.50 exercise price per share.

Is Peter Hirth’s Form 4 transaction in Aligos Therapeutics (ALGS) a buy or a sale?

The Form 4 shows an acquisition of derivative securities through a stock option grant, not an open-market buy or sale. The code “A” indicates a grant or award, reflecting compensation rather than a discretionary trading decision in Aligos shares.

How many Aligos Therapeutics (ALGS) options does Peter Hirth hold after this grant?

After this grant, Peter Hirth holds 5,860 stock options according to the filing. These options each relate to one underlying Aligos common share, giving him rights to potentially acquire that number of shares if he exercises the options after vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hirth Peter

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.5	06/25/2026		A		5,860		(1)	06/25/2036	Common Stock	5,860	$0	5,860	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

	/s/ Lesley Ann Calhoun, as attorney-in fact for Peter Hirth	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)